Lumbar Erector Spinae Plane Block Versus PENG Block for Hip Fracture Surgery
Lumbar Erector Spinae Plane Block Versus Pericapsular Nerve Group (PENG) Block in Patients With Fracture Neck of Femur Undergoing Hip Surgery: A Randomized, Double-Blind, Controlled Trial
The purpose of this clinical trial is to compare two different nerve block techniques-the Pericapsular Nerve Group (PENG) block and the Lumbar Erector Spinae Plane Block (L-ESPB)-for managing pain after hip fracture surgery in elderly patients.
Hip fractures are common in older adults and often cause significant pain. Managing this pain effectively helps patients recover faster and move around sooner after surgery. Traditional pain relief options include nerve blocks and strong pain medications (opioids). However, opioids can cause unwanted side effects like nausea and drowsiness, while some traditional nerve blocks can weaken the leg muscles, making early walking difficult.
Nerve blocks inject a local anesthetic (numbing medication) around specific nerves or within muscle layers to temporarily block pain signals:
- PENG Block: Targets the specific sensory nerves supplying the front of the hip joint while minimizing leg muscle weakness.
- Lumbar ESPB: Injects numbing medication near the lower spine to block pain signals coming from the hip region.
Participants in this study will include adults aged 60 and older undergoing hip surgery for a femoral neck fracture under spinal anesthesia. Participants will be randomly assigned (like flipping a coin) to receive either the PENG block or the Lumbar ESPB before their surgery. Both blocks are performed under ultrasound guidance to ensure precise medication placement.
Researchers will compare:
- Pain levels at rest and during movement over the first 48 hours after surgery.
- The total amount of additional pain medication (opioids) required.
- Leg muscle (quadriceps) strength after surgery.
- Any side effects or complications, as well as the overall length of hospital stay.
The findings from this study will help doctors determine which nerve block provides better pain relief while preserving leg strength, aiding in safer and faster recovery for elderly patients after hip surgery.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
BACKGROUND AND RATIONALE:
Hip fractures in elderly patients are associated with significant morbidity, prolonged hospitalization, and functional decline. Effective perioperative analgesia is crucial for early recovery. While systemic opioids and conventional nerve blocks (such as femoral or fascia iliaca blocks) provide pain relief, they are often limited by quadriceps weakness, opioid-related side effects, and delayed mobilization.
The Pericapsular Nerve Group (PENG) block targets the articular branches of the femoral, obturator, and accessory obturator nerves supplying the anterior hip capsule, offering motor-sparing analgesia. The lumbar erector spinae plane block (L-ESPB) is a paraspinal fascial plane block allowing craniocaudal local anesthetic spread to dorsal and ventral rami. Head-to-head evidence comparing L-ESPB and PENG blocks in patients with femoral neck fractures undergoing hip surgery remains limited.
STUDY PROTOCOL & INTERVENTIONS:
This prospective, randomized, double-blind, parallel-group clinical trial evaluates elderly patients (age ≥60 years, ASA II-III) undergoing hip surgery (hemiarthroplasty or total hip arthroplasty) under spinal anesthesia.
Participants are randomized in a 1:1 ratio to receive either:
- Group P: Ultrasound-guided PENG block using 20-25 mL of 0.25% bupivacaine.
- Group E: Ultrasound-guided L-ESPB at L3/L4 level using 25-30 mL of 0.25% bupivacaine.
Blocks are performed 20 minutes preoperatively by a dedicated anesthetist not involved in outcome assessment. All patients receive standardized intraoperative spinal anesthesia and postoperative multimodal systemic analgesia (scheduled IV/oral paracetamol with IV pethidine as rescue analgesia). Pain scores at rest and on movement, cumulative 24-hour opioid consumption, quadriceps strength (MRC scale), block-related complications, and length of hospital stay will be evaluated.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Kerollos Moneer Neseem Mikhael, MD
- Número de teléfono: 00201288549959
- Correo electrónico: Kmnmk87@med.bsu.edu.eg
Ubicaciones de estudio
-
-
-
Banī Suwayf, Egipto, 62515
- Beni-Suef University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 60 years or older.
- Unilateral fracture neck of femur scheduled for hip surgery (hemiarthroplasty or total hip arthroplasty) under spinal anesthesia (with or without light sedation).
- American Society of Anesthesiologists (ASA) physical status II-III.
- Ability to understand and use Numeric Rating Scale (NRS) pain scoring and to provide informed consent (or availability of a legally authorized representative according to local regulations).
Exclusion Criteria:
- Patient refusal to participate.
- Coagulopathy (platelet count < 100,000/µL, INR > 1.4) or ongoing therapeutic anticoagulation that precludes deep peripheral or neuraxial blocks per current guidelines.
- Infection at the injection site, systemic sepsis, or hemodynamic instability.
- Pre-existing significant neurological deficit in the involved lower limb, advanced peripheral neuropathy, or cognitive impairment precluding reliable pain assessment.
- Known allergy or hypersensitivity to amide local anesthetics or study medications.
- Severe chronic opioid use (defined as > 30 mg oral morphine equivalent daily for > 3 months).
- Body Mass Index (BMI) > 35 kg/m² if considered to significantly hinder ultrasound visualization, at investigator discretion.
- Prior hip surgery on the same side or severe anatomical hip deformity affecting block performance.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: PENG Block
Patients receive an ultrasound-guided Pericapsular Nerve Group (PENG) block preoperatively using 20-25 mL of 0.25% bupivacaine (50-62.5 mg) deposited in the fascial plane between the iliopsoas tendon and pubic ramus near the iliopubical eminence (IPE). Standard spinal anesthesia and postoperative multimodal systemic analgesia are administered. |
Ultrasound-guided nerve block performed 20 minutes preoperatively in the supine position. A 22G echogenic needle is directed in-plane lateral-to-medial to target the fascial plane deep to the iliopsoas tendon. Following negative aspiration and hydrodissection (2-3 mL saline), 20-25 mL bupivacaine 0.25% (or 15-20 mL in frail/small patients) is injected in 3-5 mL aliquots.
Otros nombres:
|
|
Comparador activo: Lumbar ESPB
Patients receive an ultrasound-guided Lumbar Erector Spinae Plane Block (L-ESPB) preoperatively at the L3 or L4 transverse process level using 25-30 mL of 0.25% bupivacaine (62.5-75 mg) deposited deep to the erector spinae muscle. Standard spinal anesthesia and postoperative multimodal systemic analgesia are administered. |
Ultrasound-guided fascial plane block performed 20 minutes preoperatively in the lateral decubitus or sitting position. A 22G echogenic needle is advanced in-plane cranial-to-caudal to contact the L3 or L4 transverse process. Following negative aspiration and hydrodissection confirming muscle lifting, 25-30 mL bupivacaine 0.25% is injected in 3-5 mL aliquots.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative Pain Score on Movement at 12 Hours
Periodo de tiempo: 12 hours after the end of surgery
|
Pain intensity assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Pain is evaluated during gentle passive leg movement (flexion or rotation) of the operated limb. |
12 hours after the end of surgery
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative Pain Scores at Rest and Movement at Specified Time Points
Periodo de tiempo: 30 minutes, 2 hours, 6 hours, 24 hours, and 48 hours after surgery
|
Pain intensity measured using the Numeric Rating Scale (NRS 0-10, where 0 = no pain and 10 = worst imaginable pain) at rest and during gentle passive movement of the operated limb. |
30 minutes, 2 hours, 6 hours, 24 hours, and 48 hours after surgery
|
|
Cumulative Opioid Consumption in the First 24 Hours
Periodo de tiempo: First 24 hours postoperatively
|
Total dose of intravenous pethidine (meperidine) administered as rescue analgesia in milligrams (mg). |
First 24 hours postoperatively
|
|
Time to First Rescue Analgesic Request
Periodo de tiempo: Up to 48 hours postoperatively
|
Duration of time measured in hours from the end of surgery until the patient requests the first dose of rescue IV pethidine. |
Up to 48 hours postoperatively
|
|
Quadriceps Motor Function (Knee Extension Strength)
Periodo de tiempo: At 6, 12, and 24 hours postoperatively
|
Evaluation of ipsilateral quadriceps muscle strength using the Medical Research Council (MRC) scale, ranging from 0 (no movement) to 5 (normal strength). Motor weakness is defined as an MRC grade ≤ 3/5. |
At 6, 12, and 24 hours postoperatively
|
|
Incidence of Block-Related Complications and Opioid-Related Adverse Events
Periodo de tiempo: Up to 48 hours postoperatively
|
Percentage of participants experiencing adverse events including postoperative nausea and vomiting (PONV), pruritus, urinary retention, hypotension, bradycardia, signs of local anesthetic systemic toxicity (LAST), hematoma, injection site infection, neurological deficit/nerve injury, or falls. |
Up to 48 hours postoperatively
|
|
Length of Hospital Stay
Periodo de tiempo: From date of surgery until hospital discharge (up to approximately 30 days)
|
Duration of time from surgery completion until discharge from the hospital, measured in total days. |
From date of surgery until hospital discharge (up to approximately 30 days)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Heridas y Lesiones
- Complicaciones Postoperatorias
- Procesos Patológicos
- Lesiones en las piernas
- Fracturas, Hueso
- Fracturas Femorales
- Lesiones de cadera
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor Postoperatorio
- Fracturas de cadera
- Fracturas del cuello femoral
Otros números de identificación del estudio
Otros números de identificación del estudio
- FMBSUREC/07062026b/ Mikhael
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual de-identified participant data underlying the published primary and secondary results (including demographic data, baseline characteristics, NRS pain scores, cumulative opioid consumption, quadriceps motor strength scores, and adverse events) will be made available upon reasonable request to qualified academic researchers.
Marco de tiempo para compartir IPD
Data will become available starting 6 months following publication of the primary manuscript in a peer-reviewed journal and will remain accessible for up to 3 years.
Criterios de acceso compartido de IPD
Data will be shared with researchers whose proposed use has been approved by an independent review committee or the principal investigator to achieve the aims of an approved scientific proposal. Requests should be directed to the Principal Investigator (Dr. Kerollos Moneer Neseem Mikhael) via email. A signed Data Use Agreement (DUA) may be required.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .